Drugs / Emtricitabine/tenofovir disoproxil fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01641367 | Feb 2013 → Nov 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01641367 ↗ |
| Route | Oral | “Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily” NCT01641367 ↗ |